InvestorsHub Logo
Followers 20
Posts 3273
Boards Moderated 1
Alias Born 06/05/2020

Re: moneycrew post# 209407

Thursday, 05/26/2022 1:20:39 PM

Thursday, May 26, 2022 1:20:39 PM

Post# of 233286
Believe the part in red is the answer to that question

In January 2022, the Company received a Warning Letter from the United States FDA alleging that its former CEO and President, Dr. Nader Pourhassan, had made references in a video interview to COVID-19 and leronlimab in a promotional context to the effect that leronlimab, an investigational new drug, is safe and effective for the purpose for which it is being investigated or otherwise promoted the drug. The FDA warned the Company that leronlimab has not been approved or authorized by the FDA, its safety and effectiveness has not yet been established, and that the related clinical trial data was mischaracterized in the video. The FDA further alleged the video misbrands leronlimab under section 502(f)(1) of the FD&C Act and in violation of section 301(a) of the FD&C Act, as the claims in the video make representations in a promotional context regarding the safety and efficacy of an investigational new drug that has not
39

been approved or authorized by the FDA. The Company is working closely with the FDA to resolve this matter and take the proper corrective actions.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CYDY News